AI Article Synopsis
- Hematopoietic stem cell transplantation (HSCT) is recommended for children with acute myeloid leukemia (AML) in second remission based on AML-BFM 98 trial results.
- A retrospective study analyzed data from 109 out of 152 children who underwent HSCT with a BuCyMel conditioning regimen, revealing a median age of 12.2 years at the time of the transplant.
- The study reported a 5-year overall survival rate of 62%, a relapse incidence of 35%, and 12% of patients experiencing treatment-related mortality, leading to the initiation of a new trial for better outcome data.
Article Abstract
Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2012.204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The clinical features and outcomes of elderly patients with acute myeloid leukemia: a real word research.
Clin Exp Med
January 2025
Medical Center of Hematology, Xinqiao Hospital of Army Medical University; Chongqing Key Laboratory of Hematology and Microenvironment; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, No.83 Xinqiao Main Street, Shapingba District, 400037, China.
The aim of this study was to investigate the clinical features and outcomes of elderly patients with acute myeloid leukemia (AML) from a real word research. The clinical data of 223 consecutive elderly patients (aged ≥ 60 years) who were newly diagnosed with AML at our medical center between July 2017 and June 2022, including their clinical characteristics, genetic mutations, and survival outcomes, were retrospectively analyzed. Among the 223 patients (median age 67 years), 180 (80.
View Article and Find Full Text PDFBackground: Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA-sAML) face a dismal prognosis.
Methods: The authors analyze the characteristics, therapeutic approaches, and outcomes of patients with HMA-sAML from the Programa Español para el Tratamiento de Hemopatías Malignas (PETHEMA) registry.
Results: A total of 479 patients were included, mostly from prior myelodysplastic syndrome (84%).
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
Leuk Lymphoma
January 2025
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Alterations in the RAS pathway underscore the pathogenic complexity of acute myeloid leukemia (AML), yet the full spectrum, including , , , , and , remains to be fully elucidated. In this retrospective study of 735 adult AML patients, the incidence of RAS pathway alterations was 32.4%, each with distinct clinical characteristics.
View Article and Find Full Text PDF[Research Advance of Single Cell Sequencing Technology in Acute Myeloid Leukemia--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Clinical Laboratory Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
Acute myeloid leukemia (AML) is the most common and highly heterogeneous acute leukemia in adults. Despite the continuous optimization of prognostic risk stratification and treatment regimens, the overall long-term survival rate of AML patients remains low. The emergence of single cell sequencing (SCS) technology has overcome the defects of traditional sequencing to a certain extent, and realized the transformation of the research of malignant tumors from cell population level to single cell level.
View Article and Find Full Text PDF[Expression and Function of MAIT Cells in Patients with Newly Diagnosed Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Hematology, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.
Objective: To explore the changes in number and immune function of mucosal-associated invariant T (MAIT) cells in peripheral blood of patients with newly diagnosed acute myeloid leukemia (AML), and its correlation with the occurrence and development of AML.
Methods: Seventy-five clinical samples of patients with newly diagnosed AML and 48 healthy control samples in our hospital from January 2022 to February 2023 were included. Multiparametric flow cytometry was used to detect the number of MAIT cells, membrane surface markers, effector phenotypes and functional indicators in the samples.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!